Insider · CIK 0001996255
Cheng Liu
Files at ESLA (Estrella Immunopharma, Inc.). First filing -, latest -.
In brief
Cheng Liu files SEC Form 4 as CEO and director at ESLA (Estrella Immunopharma, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Cheng Liu has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 25, 2026 | ESLA Estrella Immunopharma, Inc. | MOption exercise Common Stock, par value $0.0001 per share | +100,000 | $0.82 | $82k | 397,437 | Aug 26, 2026 |
| Aug 25, 2026 | ESLA Estrella Immunopharma, Inc. | MOption exercise Incentive Stock Optionderivative | +100,000 | $0.00 | $0 | 900,000 | Aug 26, 2026 |
| Oct 30, 2024 | ESLA Estrella Immunopharma, Inc. | AGrant or award Incentive Share Optionderivative | +490,796 | - | - | 490,796 | Feb 14, 2025 |
| Oct 30, 2024 | ESLA Estrella Immunopharma, Inc. | AGrant or award Nonstatutory Share Optionderivative | +509,204 | - | - | 509,203 | Feb 14, 2025 |
Questions about Cheng Liu
Answered from the filings on this page, as of the latest one.
Is Cheng Liu buying or selling?
Cheng Liu has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Cheng Liu's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Cheng Liu has 0.
Where does Cheng Liu file Form 4?
Cheng Liu has filed Form 4 at ESLA (Estrella Immunopharma, Inc.) as CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.